SCHEMBL4723748

SCHEMBL4723748

Cc1ccc(C2=NC(=Cc3c[nH]c4ncccc34)C(=O)N2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.50
CHEK1 O14757 2/20 0.49
ALOX5 P09917 1/20 0.48
KMT2A Q03164 2/20 0.47
CDK1 P06493 2/20 0.44
CHEK2 O96017 1/20 0.44
SRC P12931 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
HASPIN Q8TF76 4/20 0.43
CCNT1 O60563 2/20 0.43
CDK9 P50750 2/20 0.43
MAPT P10636 2/20 0.40
CDC7 O00311 4/20 0.40
NPC1 O15118 2/20 0.38
POLB P06746 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723744 1.00 RAB9A (0.50) RAB9ACHEK1ALOX5KMT2ACDK1
SCHEMBL5094570 0.90 CHEK1 (0.55) RAB9ACHEK1KMT2ACDK1CHEK2
SCHEMBL4764261 0.90 CHEK1 (0.55) RAB9ACHEK1KMT2ACDK1CHEK2
SCHEMBL5089602 0.90 CHEK1 (0.55) RAB9ACHEK1KMT2ACDK1CHEK2
SCHEMBL4879940 0.89 CHEK1 (0.49) RAB9ACHEK1KMT2ACDK1CHEK2
SCHEMBL5089748 0.89 RAB9A (0.51) RAB9ACHEK1ALOX5KMT2ACDK1
SCHEMBL4879929 0.89 CHEK1 (0.49) RAB9ACHEK1KMT2ACDK1CHEK2
SCHEMBL4724177 0.89 RAB9A (0.51) RAB9ACHEK1ALOX5KMT2ACDK1
SCHEMBL5094739 0.89 CHEK1 (0.51) RAB9ACHEK1KMT2ACDK1CHEK2
SCHEMBL5094745 0.89 CHEK1 (0.51) RAB9ACHEK1KMT2ACDK1CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 US claimed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 US claimed
EP-1960399-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Pfizer Italia S.r.l. (IT) 2008-08-27 EP disclosed
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 US disclosed
WO-2007054508-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2007-05-18 WO disclosed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K20, MAP3K6, MAP3K1 RAB9A 1382/4885CHEK1 251/4885ALOX5 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.